Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma

NCT ID: NCT01983748

Last Updated: 2022-12-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2023-12-31

Brief Summary

Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA.

200 patients will be included. The Trial is an open multicenter Phase III Trial.

Detailed Description

Trial arm A (DCaT-RNA) = Experimental intervention: Patients in arm A receive 8 vaccinations over a period of 2 years consisting of autologous, mature, monocyte-derived Dendritic Cells loaded with autologous tumor RNA (20 mio DC per vaccination); cells are given via intravenous infusions; vaccinations are followed by a 1 year observation (staging every 3 months)

Trial arm B (Observation) = Control: Patients in arm B receive standard care (observation only with staging every 3 months)

Conditions

Uveal Melanoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Biological/Vaccine; Autologous Dendritic Cells loaded with autologous Tumor RNA

Group Type: EXPERIMENTAL

Autologous Dendritic Cells loaded with autologous Tumor RNA

Intervention Type: BIOLOGICAL

B

Control, Standard of care, which is clinical control every 3 months

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Autologous Dendritic Cells loaded with autologous Tumor RNA

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Patients must suffer from melanoma of the uvea (stage T2, T3 and T4 [AJCC TNM grading 2009]).
• Uveal melanoma must be resected and display a monosomy for chromosome 3 (will be determined by a validated qualitative analysis of loss of heterozygosity). Tumor material has to be stored appropriately in RNAlater solution for RNA preparation.
• The patient has to be free of detectable tumor at the time point of study enrollment (adjuvant setting), as assessed by clinical inspection, abdominal sonography, chest X-ray and evaluation of the tumor-marker S-100..
• Patients must have a WHO performance status of 0, 1 or 2 and must be in stable medical condition.
• Patients must be between 18 and 75 years old and must be able and willing to give informed consent.
• Women of child-bearing age must have a negative pregnancy test, and must oblige to use effective contraception until at least 4 weeks after the last vaccination.
• Patients must be willing to get hospitalized for at least 4 hours following vaccination(s), and to cooperate for the whole period of the trial.
• Patients must have fully recovered from surgery.
• Signed informed consent

Exclusion Criteria

• Any other major serious illness [e.g. active systemic infections, immunodeficiency disease, clinically significant heart disease, respiratory disease, bleeding disorders, cancer etc.] or a contraindication to leukapheresis.
• Evidence for HIV-1, HIV -2, HTLV-1, HBV, or HCV infection.
• Active autoimmune disease (such as but not limited to Lupus erythematosus, autoimmune thyroiditis or uveitis, multiple sclerosis, inflammatory bowel disease). Vitiligo and pathological laboratory results (autoantibodies) without clinical symptoms are, however, not an exclusion criterion.
• Previous splenectomy or radiation therapy to the spleen.
• Patients with organ allografts.
• Concomitant treatment with chemotherapy, immunotherapy, any investigational drug and paramedical substances. Patients may receive concomitant medications to control symptoms such as analgetics, antihypertensive medication, etc.
• History of other active malignant neoplasm within the preceding 5 years (excluding non-melanoma skin cancer or carcinoma in situ of the cervix).
• Organic brain syndrome or significant psychiatric abnormality which would impede informed consent and / or AND preclude participation in the full protocol and follow up.
• Positive pregnancy test / Pregnancy or lactation. If pregnancy occurs during the course of the trial to female patients in arm A or B, the patient has to be excluded.
• Detection of metastases. If uveal melanoma metastases appear during the course of the trial, the patient has to be excluded.
• Lack of compliance of the patient.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital Lübeck

OTHER

Sponsor Role: collaborator

University Hospital Munich

OTHER

Sponsor Role: collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role: collaborator

University Hospital Homburg/Saar

UNKNOWN

Sponsor Role: collaborator

Universitätsklinikum Köln

OTHER

Sponsor Role: collaborator

University Hospital Tuebingen

OTHER

Sponsor Role: collaborator

University Hospital, Essen

OTHER

Sponsor Role: collaborator

Wuerzburg University Hospital

OTHER

Sponsor Role: collaborator

University Hospital Erlangen

OTHER

Sponsor Role: lead

Responsible Party

PD Dr. med. univ. Beatrice Schuler-Thurner

Coordinating Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Beatrice Schuler-Thurner, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Erlangen

Locations

Dept. of Dermatology, University Hospital

Erlangen, Bavaria, Germany

University Hospital Department of Ophtalmology

Erlangen, Bavaria, Germany

University Hospital Department of Ophtalmology

Würzburg, Bavaria, Germany

Städtisches Klinikum

Dessau, , Germany

University Hospital Department of Ophtalmology

Essen, , Germany

University Hospital Department of Ophtalmology

Homburg/Saar, , Germany

University Hospital Department of Ophtalmology

Lübeck, , Germany

University Hospital Department of Ophtalmology

Tübingen, , Germany

Countries

Germany

References

Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N, Cursiefen C, Fuisting B, Grisanti S, Heindl LM, Holbach L, Keseru M, Knorr H, Koch K, Kruse F, Meiller R, Metz C, Meyer-ter-Vehn T, Much M, Reinsberg M, Schliep S, Seitz B, Schuler G, Susskind D, Viestenz A, Wagenfeld L, Zeschnigk M. [Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma]. Ophthalmologe. 2015 Dec;112(12):1017-21. doi: 10.1007/s00347-015-0162-z. German.

Reference Type: BACKGROUND

PMID: 26602097 (View on PubMed)

Other Identifiers

DERMA-ER-DC 08

Identifier Type: -

Identifier Source: org_study_id